Growth Factors & Signaling

MK-677 (Ibutamoren)

For Research Use Only. Not for Human or Veterinary Use.

Overview

MK-677 (Ibutamoren) is a non-peptide, orally active agonist of the growth-hormone-secretagogue receptor (GHSR-1a) — the ghrelin receptor. Although it sits in this “growth peptides” category, it is a small molecule, not a peptide. By mimicking ghrelin it stimulates the body’s own pulsatile growth-hormone release and raises IGF-1, and it has been studied for lean mass, bone density and metabolic endpoints. It is a research compound.

Chemical Profile

PropertyValue
CAS number159634-47-0 (free base)
ClassNon-peptide GHSR-1a agonist (ghrelin mimetic)
Molecular formulaC₂₇H₃₆N₄O₅S (free base)
Molecular weight528.66 g/mol (free base)
Chemical typeSmall molecule (spiro-indoline), not a peptide
Purity (HPLC)≥ 98%
AppearanceWhite to off-white powder
MK-677 at a glance
Class
Non-peptide GHSR-1a agonist
Originator
Merck & Co.
Research status
Investigational; GH / metabolic research
Study route
Oral
Half-life
≈ 24 h (once-daily)
Key feature
Orally active, long-acting GH secretagogue

Mechanism of Action

MK-677 binds the ghrelin receptor (GHSR-1a) on the pituitary and hypothalamus, reproducing ghrelin’s signal to release growth hormone. Because it amplifies the body’s own GH pulses rather than supplying GH directly, it is studied as a way to raise GH and IGF-1 while keeping the natural pulsatile pattern. Its oral activity and long half-life set it apart from the injectable peptide secretagogues.

ComponentDetail
Primary targetGHSR-1a (ghrelin receptor)
Receptor classG-protein-coupled receptor
G-protein couplingGαq/11 → PLC → IP₃/DAG → intracellular Ca²⁺
Pituitary effectDirect stimulation of somatotroph GH secretion
Hypothalamic effectEnhances GHRH, blunts somatostatin
IGF-1Sustained increase in circulating IGF-1
SystemStudied effect
MuscleIncreased lean body mass (GH/IGF-1)
BoneIncreased bone-mineral density in models
AdiposeGH-mediated lipolysis
SleepEnhanced slow-wave sleep
AppetiteIncreased (ghrelin-receptor activation)

Pharmacology

ParameterValue
Half-life (t½)≈ 24 h
Bioavailability (oral)> 60% (estimated)
Time to peak (Tmax)≈ 1–2 h
Protein binding> 99% (albumin, α₁-acid glycoprotein)
MetabolismHepatic (CYP3A4)
Route of administrationOral
EliminationRenal and fecal

Research Evidence

MK-677 has both preclinical and clinical literature spanning GH physiology, body composition and bone. Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.

Study typeResearch focusReference
Rat pituitary cellsDose-dependent GH release (GHSR agonism)Jacks T, et al.
Healthy-volunteer study24-h GH AUC and IGF-1Chapman IM, et al.
Elderly, 2-year studyLean body mass and bone densityNass R, et al. (2008)
Obese subjectsVisceral fat and insulin sensitivityGH-secretagogue literature

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Increased 24-h GH and IGF-1healthy-volunteer studyChapman IM et al.
Increased lean mass and bone density over 2 yearsolder adultsNass R et al., 2008
Preserved GH pulsatility with oral, once-daily dosingGH-physiology studiesMK-677 literature

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Handling Reference

Handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dose range (literature)≈ 10–25 mg daily (oral), in study protocols
FormOral (small molecule; no reconstitution)
StorageRoom temperature, desiccated, protected from light
Do not useIf material shows discoloration or degradation

Safety Profile

Published research observations, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
Most commonIncreased appetite, transient fatigue, mild fluid retention
MetabolicTransient insulin resistance / glucose elevation in some studies
EndocrineGH / IGF-1 elevation; mild cortisol change reported
InteractionsCYP3A4 substrate — interactions with CYP3A4 inhibitors/inducers
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white powder
Solubility (water)Poor; soluble in DMSO / organic solvents
logP (octanol/water)≈ 3.2 (lipophilic)
Chemical classSpiro-indoline small molecule
StabilityStable at room temperature when desiccated and dark

Synthesis & Manufacturing

Unlike the peptide secretagogues in this category, MK-677 is made by multi-step organic synthesis (it is a spiro-indoline small molecule), then purified by chromatography and characterised by NMR and mass spectrometry rather than by peptide methods.

  • Multi-step solution-phase organic synthesis
  • Chromatographic purification to research grade
  • Identity confirmed by NMR and mass spectrometry; purity by HPLC

Analytical Methods

As a small molecule (not a peptide), MK-677 is characterised by the standard organic-chemistry panel — NMR and mass spectrometry for structure, HPLC for purity — rather than by peptide-specific assays.

MethodPurposeTypical result
RP-HPLC (C18, UV 220/254 nm)Purity≥ 98%
¹H / ¹³C NMRStructure confirmationConsistent with the spiro-indoline structure
ESI-MS / HRMSIdentity / accurate mass[M+H]⁺ ≈ 529 Da
IR spectroscopyFunctional-group confirmationConsistent with amide / sulfonyl groups
Melting point / DSCIdentity / polymorphSharp, characteristic
Karl FischerWater contentLow (per specification)
Residual solvents (GC)ICH Q3C limitsWithin limits
Heavy metals / ICP-MSElemental impuritiesWithin limits

Representative HPLC method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase: aqueous buffer / acetonitrile gradient · Flow rate: 1.0 mL/min
  • Detection: UV 220 nm (and 254 nm) · Identity confirmed by NMR + HRMS

Stability Data

ConditionDurationResult
Solid, 2–8°C, desiccated, dark≥ 36 monthsStable
Solid, room temperature, desiccated≥ 24 monthsStable
Solid, 40°C (accelerated)3 monthsNo significant degradation
In DMSO / organic solvent, −20°CMonthsStable if kept cold and dark
In aqueous solutionLimitedPoorly water-soluble; prepare fresh
Photostability (ICH Q1B)StandardProtect from light
  • The free base is a stable crystalline solid; keep desiccated and protected from light.
  • It is only sparingly water-soluble — for in-vitro work dissolve in DMSO first, then dilute; prepare aqueous dilutions fresh.

Selected References

  • Patchett AA, et al. Design and biological activities of L-163,191 (MK-0677), an orally active growth-hormone secretagogue. Proceedings of the National Academy of Sciences.
  • Chapman IM, et al. Oral administration of the growth-hormone secretagogue MK-677 increases GH and IGF-1. Journal of Clinical Endocrinology & Metabolism.
  • Nass R, et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Annals of Internal Medicine, 2008.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by NMR and mass spectrometry
  • Research quantities through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need MK-677 — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote